Bonum Therapeutics, Inc.

Biotech Seattle, WA

About

Issuer

Entity type
Corporation
Jurisdiction
Delaware
Sector
Biotech
Headquarters
Seattle, WA
Street
1150 Eastlake Avenue E
Zip
98109

Offering

Total offering
$32.3M
Amount sold
$26.9M
First sale
Apr 3, 2026
Min investment
$0
Securities
Equity
Federal exemption
Rule 506(b)
Investors so far
8

How this filing compares

Ranked #6 of 47 Biotech filings in April 2026 by offering amount.

Median Biotech filing in April 2026: $3M. This offering is 10.8× the median.

Other Washington filings this week: Agent Venture Fund, LP - B1, Amplify Renewables Investments LP, Angel Collective Opportunity Fund, LP - F1, Beyond-FI-0210 Fund II, a series of Platform Funds 2026, LP, Bija-NO-0211 Fund I, a series of Platform Funds 2026, LP

Leadership

John Mulligan — Executive Officer (also: Director, Promoter)

John McKearn — Director

Monique Schiersing — Director

Nicholas Walrod — Director

Karl Handelsman — Director

Diane Hollenbaugh — Executive Officer

Neela Patel — Executive Officer

Mitchell Mutz — Director

Also named on: Omniox, Inc.

Samuel Bjork — Director

Gaurav Aggarwal — Director

Also named on: Vivo Opportunity Co-Invest (Cycle 3), L.P.

Samuel Blackman — Director

Filing details

Bonum Therapeutics, Inc. filed a Form D with the SEC on April 17, 2026.

Other newest Biotech companies

Other newest companies in Washington